Fenoldopam mesylate

Fenoldopam mesylate is a synthetic benzazepine derivative which acts as a selective D1 receptor partial agonist. Fenoldopam is used as an antihypertensive agent. It was approved by the Food and Drug Administration (FDA) in September 1997. Since fenoldopam is the only intravenous agent that improves renal perfusion, in theory it could be beneficial in hypertensive patients with concomitant renal insufficiency. (In Vitro) :Fenoldopam is a partial agonist with low efficacy at DA1 receptors linked to cAMP generation in the LLC-PK1 cells.Fenoldopam (0-300 μM; 48 or 72 h) displays significant antiproliferative activity against RCC cell lines.Fenoldopam (5 μM and 10 μM; 72 h) induces cell apoptosis in a dose-dependent manner. (In Vivo) :Fenoldopam mesylate (subcutaneous injection; 100 mg/kg; once daily; 2 d) can induce arteritis in rats detected by magnetic resonance imaging (MRI) .